King’s College Hospital

King’s MND Care and Research Centre

The King’s MND Care and Research Centre is a multidisciplinary team of clinical and research staff, seeing about 200 new patients a year, providing state of the art care coupled with access to cutting edge research to accelerate the search for a cure.

King’s MND Care and Research Centre

The King’s MND Care and Research Centre is a multidisciplinary team of clinical and research staff, funded by the NHS, government grants and charity grants. We see about 200 new patients a year, with a further 400 follow-up slots in neurology and hundreds more in related services as needed. Our teams include neurology, respiratory, nutritional and palliative medical and allied health professional staff, with clinical trials teams, laboratory researchers and statistical and computing expertise. We provide state-of-the-art care coupled with access to cutting edge research. We aim to accelerate the search for a cure by combining clinical care with clinical research, and collaborate internationally to increase our chances of success.

Contact
Location
King's College Hospital, Denmark Hill, London, UK

Our Specialists

Ammar Al-Chalabi

Professor of Neurology and Complex Disease Genetics

Professor Ammar Al-Chalabi is head of the Basic and Clinical Neuroscience Department at […]

Ammar Al-Chalabi
Current trials
Recruiting
Phase iii

ATLAS trial

Industry trial
Biogen is conducting a clinical trial to evaluate the efficacy and safety and of an investigational drug for adults who do not have any clinical signs or symptoms of Amyotrophic Lateral Sclerosis (ALS) (that definitely indicate the onset of ALS) but do carry a certain superoxide dismutase 1 (SOD1) gene variant.
Read more
Recruiting
Phase iii

FUSION trial

Industry trial
In this study we investigate the safety and efficacy of the study drug ‘ION363’ for the treatment of ALS caused by mutations in the FUS gene. About 1% to 5% of ALS cases are caused by FUS mutations.
Read more
Active
Phase iii

PHOENIX trial

Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Read more
Active
Phase iii

ADORE trial

Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Read more
Recruiting
Phase iii

COURAGE-ALS Trial

Industry trial
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
Read more
Active
Phase ii

APL2-ALS-206 Trial

Industry trial
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
Read more
Active
Phase iii

TUDCA-ALS

Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Read more